Equities Analysts Set Expectations for DRUG FY2025 Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG) – HC Wainwright raised their FY2025 earnings per share (EPS) estimates for shares of Bright Minds Biosciences in a note issued to investors on Monday, November 10th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($1.84) for the year, up from their prior forecast of ($1.86). HC Wainwright currently has a “Buy” rating and a $85.00 target price on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Bright Minds Biosciences’ Q4 2025 earnings at ($0.88) EPS, Q1 2026 earnings at ($0.97) EPS, Q2 2026 earnings at ($1.28) EPS, Q3 2026 earnings at ($1.56) EPS, Q4 2026 earnings at ($1.81) EPS, FY2026 earnings at ($5.69) EPS, FY2027 earnings at ($5.79) EPS, FY2028 earnings at ($5.87) EPS, FY2029 earnings at ($1.73) EPS and FY2030 earnings at $0.59 EPS.

Bright Minds Biosciences (NASDAQ:DRUG) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.06.

A number of other research analysts have also weighed in on the stock. Wall Street Zen lowered shares of Bright Minds Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, October 3rd. BTIG Research started coverage on Bright Minds Biosciences in a report on Monday, September 8th. They set a “buy” rating and a $72.00 target price for the company. Finally, Zacks Research raised Bright Minds Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 13th. Two investment analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to MarketBeat, Bright Minds Biosciences presently has a consensus rating of “Buy” and an average price target of $81.00.

Bright Minds Biosciences Stock Down 0.1%

Shares of NASDAQ DRUG opened at $59.24 on Wednesday. The firm has a market cap of $417.05 million, a price-to-earnings ratio of -63.70 and a beta of -6.27. The company’s 50-day simple moving average is $54.81 and its 200-day simple moving average is $39.85. Bright Minds Biosciences has a 52-week low of $23.17 and a 52-week high of $70.23.

Hedge Funds Weigh In On Bright Minds Biosciences

A number of institutional investors have recently bought and sold shares of DRUG. Goldman Sachs Group Inc. purchased a new stake in shares of Bright Minds Biosciences during the 1st quarter valued at approximately $802,000. Adage Capital Partners GP L.L.C. grew its position in Bright Minds Biosciences by 50.9% in the first quarter. Adage Capital Partners GP L.L.C. now owns 200,000 shares of the company’s stock worth $7,214,000 after acquiring an additional 67,500 shares during the period. OMERS ADMINISTRATION Corp acquired a new stake in Bright Minds Biosciences during the first quarter worth $505,000. AdvisorShares Investments LLC raised its position in Bright Minds Biosciences by 28.4% in the second quarter. AdvisorShares Investments LLC now owns 14,481 shares of the company’s stock valued at $378,000 after purchasing an additional 3,200 shares during the period. Finally, Millennium Management LLC lifted its stake in shares of Bright Minds Biosciences by 376.9% in the 1st quarter. Millennium Management LLC now owns 192,557 shares of the company’s stock valued at $6,946,000 after purchasing an additional 152,178 shares during the last quarter. 40.52% of the stock is owned by hedge funds and other institutional investors.

About Bright Minds Biosciences

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.